• Product NameCARD9 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationCARD9 Antibody is DEAE purified.
• ApplicationsELISA WB ICC
• Species ReactivityHu
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a synthetic peptide corresponding to amino acids 521 to 536 of human CARD9. The sequence is different from that of rat origin by two amino acids.
• Target NameCARD9
• Accession No. Swiss-Prot:Q9H257
  Gene ID:64170
• UniprotQ9H257
• Gene ID64170;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

• Predicted MW: 59 kd
  

Apoptosis is related to many diseases and development. Cell death signals are transduced by death domain (DD), death effector domain (DED), and caspase recruitment domain (CARD) containing molecules. CARD containing proteins include some caspases, Apaf-1, CARD4, IAPs, RICK, ARC, RAIDD, BCL-10, and ASC. A novel CARD-containing protein was recently identified and designated CARD9, which interacts with the CARD activation domain of BCL-10. CARD9 associates with BCL-10 and forms a complex within cells. CARD9 induces apoptosis and activates NF-κB. CARD9 is an upstream activator of BCL-10 and NF-κB signaling.

• Western blot analysis of CARD9 expression in human MDA-MB-361 (A) and PC-3 (B) cell lysate with CARD9 antibody at 2.5 ug /ml.
• Immunocytochemistry of CARD9 in K562 cells with CARD9 antibody at 10 ug/ml.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting